Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases. Allenaâs second product candidate, ALLN-346, is in preclinical development for patients with hyperuricemia and moderate to severe CKD. Hyperuricemia, or elevated levels of uric acid in the blood, is commonly associated with gout as well as kidney stones and kidney disorders. Source
No articles found.
Modern Alkeme is the everyday detox you need for your everyday life. This ready-to...
Modern Alkeme is the everyday detox you need fo...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
Restoration Robotics, Inc., (San Jose, CA) is a medical device company developing ...
Restoration Robotics, Inc., (San Jose, CA) is a...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
Join the National Investor Network and get the latest information with your interests in mind.